GHRS — GH Research PLC stock price, charts and financials

Latest market price

29.12

+0.93+3.30%

Overview Short InterestFilings

GHRSQT87GH Research PLC·NASDAQ

Overview Short InterestFilings

29.12+3.30%

Earnings

Up 3.3% — Earnings due 2026-08-06 — pre-report positioning.

Medium confidence

Loading chart...

Screen all →

IOVA+0.93%$4.36 RAPP+3.46%$42.20 TYRA+1.53%$32.53 ZBIO+0.93%$31.42 NBTX+1.62%$39.52 URGN+3.45%$39.92 MESO+2.28%$14.80 AUPH+2.47%$14.93

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	68.56M	Perf Week	1.59%

Market Cap	1.93B	Forward P/E	-	EPS next Y	-1.88	Insider Trans	-	Shs Float	50.88M	Perf Month	4.37%

Enterprise Value	1.78B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	3.82%	Perf Quarter	36.12%

Income	-48.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	7.45	Perf Half Y	80.01%

Sales	0.00	P/B	9.20	EPS next Y	-38.57%	ROA	-20.49%	Short Interest	1.95M	Perf YTD	121.97%

Book/sh	3.06	P/C	12.23	EPS next 5Y	-	ROE	-19.83%	52W High	32.02 -9.06%	Perf Year	96.31%

Cash/sh	2.30	P/FCF	-	EPS past 3/5Y	-	ROIC	-25.28%	52W Low	11.69 149.03%	Perf 3Y	112.59%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	4.09% 5.35%	Perf 5Y	68.50%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-22.67%	Oper. Margin	0.00%	ATR (14)	1.51	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	23.04	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	58.25	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	23.04	EPS Q/Q	-63.16%	SMA20	2.13%	Beta	1.31	Target Price	42.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	12.55%	Rel Volume	0.92	Prev Close	28.19

Employees	73	LT Debt/Eq	0.00	Earnings	Aug 06	SMA200	56.49%	Avg Volume	263.11K	Price	29.12

IPO Date	Jun 25, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.68% -	Net Debt/EBITDA	4.34	Volume	241,240	Change	3.30%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-27-26	Initiated	Wells Fargo	Overweight	$44
May-19-26	Reiterated	HC Wainwright & Co.	Buy	$35 → $65
May-15-26	Reiterated	Cantor Fitzgerald	Overweight	$35
Mar-10-26	Reiterated	Guggenheim	Buy	$29 → $34
Mar-06-26	Reiterated	Needham	Buy	$29 → $32
Jan-23-26	Reiterated	RBC Capital	Outperform	$40
Jan-06-26	Reiterated	Wolfe Research		$39
Jan-06-26	Reiterated	Canaccord Genuity	Buy	$28 → $39
Jan-06-26	Reiterated	Needham	Buy	$19 → $29
Jan-05-26	Reiterated	Guggenheim	Buy	$29

Latest News

Jul-27-26

Jul-27-2608:49AM

Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44Benzinga

Jul-16-26

Jul-16-2612:36PM

Why Is GH Research Stock Trading Higher on Thursday?Benzinga

Jul-14-26

Jul-14-2607:53AM

CleanSpark shares surge after company secures $6.6B data center lease agreementproactiveinvestors.com

07:20AM

Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacityproactiveinvestors.com

Jul-13-26

Jul-13-2603:18PM

Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies saysproactiveinvestors.com

Company

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0
Selling, General and Administrative Excl. Other	22	15	11	10	7	0	0
Research and Development	39	35	30	20	9	0	0
Other Operating Expense	-1	0	0	1	-1	0	0
Operating Income	-61	-50	-41	-31	-15	0	0
Interest Expense	0	1	1	—	0	0	0
Unusual Expense	—	—	—	—	—	—	—
Non-Operating Income (Expense)	13	12	6	8	6	0	0
Net Income Before Taxes	-48	-39	-36	-22	-9	0	0
Income Taxes	0	0	0	0	0	0	0
Consolidated Net Income	-48	-39	-36	-22	-9	0	0
Net Income From Continuing Operations	-48	-39	-36	-22	-9	0	0
Net Income	-48	-39	-36	-22	-9	0	0
EPS (Recurring)	-0.79	-0.75	-0.68	-0.14	-0.18	-0.01	-0.01
EPS (Basic, Before Extraordinaries)	-0.79	-0.75	-0.68	-0.14	-0.18	-0.01	-0.01
EPS (Diluted)	-0.79	-0.75	-0.68	-0.14	-0.18	-0.01	-0.01
EBITDA	-47	-39	-35	-22	-9	0	0
Other After Tax Adjustments	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—
Shares Outstanding	61	52	52	52	52	30	28
Market Capitalization	775	364	302	505	1,213	—	—
Operating Lease Expense	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.